ClinicalTrials.gg
RecruitingNCT07371832Updated Oct 8, 2026

A Single Center Evaluation of AI Enabled SureForm Robotic Stapler (SureformTM) Compared to Conventional Stapler for Colorectal Cancer Procedures

An observational study in Colorectal Cancer, sponsored by Asian Institute of Gastroenterology, India. Recruiting at 1 site in India. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Asian Institute of Gastroenterology, India · Observational

How we know

From the registry’s dates

  • Started Jan 2026; still recruiting 10 months later.
Updated Oct 8, 2026Start date movedEligibility revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
200
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Colorectal Neoplasms with a site in India — 8 open to participants now, 13 under way, 7 of them phase 3. Colorectal Neoplasms · India.

Started
2026
with 1 other
Observational
5 of 33
2 open now
Primary completion
2028-02
later than 8 of 12 live
Registered
31st of 33
by date
Lead sponsor
1 of 33
Asian Institute of Gastroenterology, India

Among the 33 studies in Colorectal Neoplasms with a site in India, this one is one of 2 that started in 2026, is one of 5 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 31st registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

8 of the 33 studies in Colorectal Neoplasms with a site in India are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Colorectal Neoplasms with a site in India, or all of them as a file.
02

Study summary

Robotic-assisted surgeries are especially valuable for colorectal pathologies because they offer better vision and control for surgical manipulation given the narrow operative region within the pelvis .Some of the iatrogenic risk factors associated with higher post-operative adverse events following colorectal surgeries are surgeon experience' and hospital case load'. In order to mitigate these factors, surgical staplers have gained preference amongst surgeons due to their reproducible results and ease of learning At present there are only two methods of creating an anastomosis: hand-sewn technique using sutures or surgical staplers. Surgical staplers have been shown to be as effective as hand-sewn techniques for colorectal anastomoses However, anastomotic strictures can be bothersome for patients and the rate of stricture is fourfold higher for stapled anastomoses than for those that are hand sewn in colorectal anastomoses . Additionally, overzealous or incorrect stapling could also result in hemostasis or ischemia One of the most dreaded adverse events of colorectal resection is anastomotic leakages followed, in decreasing severity, by post-operative bleeding and ileus. Because of the severity of adverse events associated with an anastomotic leak, it is important to detect it early and provide early management for the same. However, diagnosis of anastomotic leakage is commonly a symptomatic diagnosis based on development of gas, purulent or fecal discharge from the drain, purulent discharge from the rectum, pelvic abscess or peritonitis. Such severe symptoms further complicate the post-operative recovery and lengthen the hospital stay. Interestingly, it has been

reported that anastomotic leaks were more often diagnosed late in the postoperative period and more often after hospital discharge, or 12 days postoperatively . Anastomotic leakage rates vary from the colon to the rectum, with much higher rates in the rectum. Because of the severity of adverse events associate with an anastomotic leak, there is a pressing need for new techniques for prevention of anastomotic leakages .

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

The criteria were revised on the registry on Oct 8, 2026. See what changed

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

200

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is 18 to 85 years of age
  • Subjects who will undergo Planned robotic-assisted surgery or laparoscopic surgery (as the primary treatment) for non- colorectal cancer where staplers are utilized for transection and/or creation of anastomosis

Exclusion criteria

Exclusion criteria:

  • Emergency Surgery for non- colorectal cancer
  • Subjects who are being treated for recurrent colorectal cancer
  • Subjects who will require extensive dissection to release adhesions or with advanced cancer which may result in anastomotic leak and/or bleeding unrelated to the stapler
  • Subjects who have perforated, obstructing or locally invasive neoplasm (T4b)
  • Subjects who have major concomitant abdominal or pelvic procedures (e.g. hepatectomies, incisional ventral hernia repair, nephrectomies, hysterectomy) planned along with surgery for colorectal cancer
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Robotic-Assisted Surgery Group (Intervention Arm)

    Subjects undergoing robotic-assisted colorectal cancer surgery where AI-enabled SureForm™ Robotic.Stapler is used for bowel transection and/or creation of anastomosis.

    Device: AI-enabled SureForm™ Robotic Stapler · Device: Conventional Laparoscopic Stapler

  • Laparoscopic Surgery Group (Comparator Arm)

    Subjects undergoing laparoscopic colorectal cancer surgery using conventional laparoscopic staplers for bowel transection and/or creation of anastomosis.

    Device: AI-enabled SureForm™ Robotic Stapler · Device: Conventional Laparoscopic Stapler

Interventions

  • DeviceAI-enabled SureForm™ Robotic Stapler

    Use of AI-enabled SureForm™ robotic stapler during robotic-assisted colorectal resections for transection and/or anastomosis creation.

  • DeviceConventional Laparoscopic Stapler

    Use of standard conventional laparoscopic staplers during laparoscopic colorectal resections for transection and/or anastomosis creation

06

What researchers measure

Primary outcomes

  1. Anastomotic leak rate

    Percentage of participants diagnosed with an anastomotic leakage (confirmed clinically by gas, purulent/fecal discharge from the drain/rectum, pelvic abscess, peritonitis, or via radiological imaging/reoperation) following colorectal resection

    Time frame: From time of surgery through 30 days post-operatively.

  2. Percentage of Participants Requiring a Surgical Stapler Articulation Angle Greater Than 45 Degrees

    Proportion of participants in whom surgical transection required a robotic wrist articulation angle exceeding 45 degrees (calculated as resultant 3D vector articulation: square root of pitch squared plus yaw squared). Additional telemetry parameters recorded include mean pitch and yaw angles, number of clamping attempts, and successful firing completion rates.

    Time frame: Intra-operative (during the surgical procedure)

  3. Other Complications Attributable to Stapler Use

    Time frame: From intra-operative procedure through 30 days post-operatively.

Secondary outcomes

  1. Operative time

    Operative time is defined as the total duration of the surgical procedure, measured in minutes, from skin incision to completion of skin closure.

    Time frame: 24 MONTHS

  2. Increase in Operative Time Due to Stapling Complications

    Additional intra-operative time (in minutes) expended specifically to manage, troubleshoot, or repair staple-line-related issues or device malfunctions (such as over-sewing bleeding staple lines, applying hemostatic sealants, or redoing an anastomosis).

    Time frame: Intra-operative (day of surgery).

  3. Intraoperative and Postoperative Adverse Events

    Rate and severity of procedure-related complications categorized according to the Clavien-Dindo classification system, including requirements for intra-operative or post-operative blood transfusion.

    Time frame: From initiation of surgery through 30 days post-operatively.

  4. Rate of Intracorporeal Anastomosis

    Proportion of cases where the bowel anastomosis was constructed completely intracorporeally versus extracorporeally.

    Time frame: Intra-operative (day of surgery)

  5. Surgical Conversion Rate

    Percentage of minimally invasive procedures (robotic or laparoscopic) converted to an unplanned open laparotomy or hand-assisted approach.

    Time frame: Intra-operative (day of surgery).

  6. Conversion Rate Due to Stapling-Related Complications

    Percentage of conversions to open surgery or hand-assisted techniques directly resulting from stapler misfires, device failure, or intractable staple-line failure.

    Time frame: Intra-operative (day of surgery)

  7. Length of ICU Stay

    Total duration of intensive care unit admission recorded in continuous days.

    Time frame: From immediate post-operative transfer until discharge from the ICU (assessed up to 30 days post-surgery).

  8. Increase in ICU Stay Due to Stapling Complications

    Additional days spent in the intensive care unit directly attributable to the management and recovery from staple-line leaks, bleeding, or reinterventions.

    Time frame: From immediate post-operative period through hospital discharge (assessed up to 30 days post-surgery).

  9. Total Length of Hospital Stay

    Time frame: From date of surgery through index hospital discharge (assessed up to 30 days post-surgery).

  10. Increase in Hospital Stay Due to Stapling Complications

    Time frame: Through index hospital discharge (assessed up to 30 days post-surgery).

  11. Resection Margin Positivity Rate

    Time frame: Through final histopathology reporting (typically within 14 to 30 days post-surgery).

  12. Percentage of Participants With Complete Mesorectal Excision Quality Graded by Quirke Classification

    Time frame: Through final histopathology reporting (typically within 14 to 30 days post-surgery).

  13. Number of Regional Lymph Nodes Harvested per Participant

    Total count of regional lymph nodes harvested and histopathologically examined from the resected colorectal surgical specimen. Data will be reported as the mean or median number of lymph nodes retrieved per participant.

    Time frame: Through final histopathology reporting (typically within 14 to 30 days post-surgery).

  14. 30-Day Hospital Readmission Rate

    Time frame: From hospital discharge up to 30 days post-surgery.

  15. 30-Day Reoperation Rate

    Time frame: From completion of surgery through 30 days post-surgery.

  16. Time to Initiation of Adjuvant Therapy

    Time frame: From date of surgery up to 30 days post-surgery (or standard post-operative follow-up window).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Feb 2028, 25 months after the start.

Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 25 months is below that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Jan 2026, on Oct 8, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Jan 28, 2026
StartActual
Jan 19, 2026was Feb 2026
Primary completionEst.
Feb 28, 2028
CompletionEst.
Feb 28, 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Feb 5, 2026→Jan 19, 2026
Oct 8, 2026
Eligibility
Maximum age 80 Years→85 Years; 1 inclusion criterion edited, 1 added; 5 exclusion criteria added, 1 removed
What changed in the criteria
Inclusion criteria
  • AddedSubject is 18 to 85 years of age
  • EditedSubjects, 18 to 90 years B. Subjects who will undergo Planned robotic-assisted surgery or laparoscopic surgery (as the primary treatment) for non-metastatic colorectal cancer where staplers are utilized for transection and/or creation of anastomosis
Exclusion criteria
  • RemovedA. Emergency Surgery for non-metastatic colorectal cancer B. Subjects who are being treated for recurrent colorectal cancer C. Subjects who will require extensive dissection to release adhesions or with advanced cancer which may result in anastomotic leak and/or bleeding unrelated to the stapler D. Subjects who have perforated, obstructing or locally invasive neoplasm (T4b) E. Subjects who have major concomitant abdominal or pelvic procedures (e.g. hepatectomies, incisional ventral hernia repair, nephrectomies, hysterectomy) planned along with surgery for colorectal cancer
  • AddedEmergency Surgery for non-metastatic colorectal cancer
  • AddedSubjects who are being treated for recurrent colorectal cancer
  • AddedSubjects who will require extensive dissection to release adhesions or with advanced cancer which may result in anastomotic leak and/or bleeding unrelated to the stapler
  • AddedSubjects who have perforated, obstructing or locally invasive neoplasm (T4b)
  • AddedSubjects who have major concomitant abdominal or pelvic procedures (e.g. hepatectomies, incisional ventral hernia repair, nephrectomies, hysterectomy) planned along with surgery for colorectal cancer
Oct 8, 2026
Primary outcomes
1 edited, 2 added
What changed in the outcomes
  • EditedAnastomotic leak ratesrateTime frame: 24 MONTHS → From time of surgery through 30 days post-operatively.
  • AddedPercentage of Participants Requiring a Surgical Stapler Articulation Angle Greater Than 45 DegreesTime frame: Intra-operative (during the surgical procedure)
  • AddedOther Complications Attributable to Stapler UseTime frame: From intra-operative procedure through 30 days post-operatively.
Oct 8, 2026
Secondary outcomes
15 added
What changed in the outcomes
  • AddedIncrease in Operative Time Due to Stapling ComplicationsTime frame: Intra-operative (day of surgery).
  • AddedIntraoperative and Postoperative Adverse EventsTime frame: From initiation of surgery through 30 days post-operatively.
  • AddedRate of Intracorporeal AnastomosisTime frame: Intra-operative (day of surgery)
  • AddedSurgical Conversion RateTime frame: Intra-operative (day of surgery).
  • AddedConversion Rate Due to Stapling-Related ComplicationsTime frame: Intra-operative (day of surgery)
  • AddedLength of ICU StayTime frame: From immediate post-operative transfer until discharge from the ICU (assessed up to 30 days post-surgery).
  • AddedIncrease in ICU Stay Due to Stapling ComplicationsTime frame: From immediate post-operative period through hospital discharge (assessed up to 30 days post-surgery).
  • AddedTotal Length of Hospital StayTime frame: From date of surgery through index hospital discharge (assessed up to 30 days post-surgery).
  • AddedIncrease in Hospital Stay Due to Stapling ComplicationsTime frame: Through index hospital discharge (assessed up to 30 days post-surgery).
  • AddedResection Margin Positivity RateTime frame: Through final histopathology reporting (typically within 14 to 30 days post-surgery).
  • AddedPercentage of Participants With Complete Mesorectal Excision Quality Graded by Quirke ClassificationTime frame: Through final histopathology reporting (typically within 14 to 30 days post-surgery).
  • AddedNumber of Regional Lymph Nodes Harvested per ParticipantTime frame: Through final histopathology reporting (typically within 14 to 30 days post-surgery).
  • Added30-Day Hospital Readmission RateTime frame: From hospital discharge up to 30 days post-surgery.
  • Added30-Day Reoperation RateTime frame: From completion of surgery through 30 days post-surgery.
  • AddedTime to Initiation of Adjuvant TherapyTime frame: From date of surgery up to 30 days post-surgery (or standard post-operative follow-up window).
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Start date Feb 5, 2026→Jan 19, 2026
    Eligibility Maximum age 80 Years→85 Years; 1 inclusion criterion edited, 1 added; 5 exclusion criteria added, 1 removed
    What changed in the criteria
    Inclusion criteria
    • AddedSubject is 18 to 85 years of age
    • EditedSubjects, 18 to 90 years B. Subjects who will undergo Planned robotic-assisted surgery or laparoscopic surgery (as the primary treatment) for non-metastatic colorectal cancer where staplers are utilized for transection and/or creation of anastomosis
    Exclusion criteria
    • RemovedA. Emergency Surgery for non-metastatic colorectal cancer B. Subjects who are being treated for recurrent colorectal cancer C. Subjects who will require extensive dissection to release adhesions or with advanced cancer which may result in anastomotic leak and/or bleeding unrelated to the stapler D. Subjects who have perforated, obstructing or locally invasive neoplasm (T4b) E. Subjects who have major concomitant abdominal or pelvic procedures (e.g. hepatectomies, incisional ventral hernia repair, nephrectomies, hysterectomy) planned along with surgery for colorectal cancer
    • AddedEmergency Surgery for non-metastatic colorectal cancer
    • AddedSubjects who are being treated for recurrent colorectal cancer
    • AddedSubjects who will require extensive dissection to release adhesions or with advanced cancer which may result in anastomotic leak and/or bleeding unrelated to the stapler
    • AddedSubjects who have perforated, obstructing or locally invasive neoplasm (T4b)
    • AddedSubjects who have major concomitant abdominal or pelvic procedures (e.g. hepatectomies, incisional ventral hernia repair, nephrectomies, hysterectomy) planned along with surgery for colorectal cancer
    Primary outcomes 1 edited, 2 added
    What changed in the outcomes
    • EditedAnastomotic leak ratesrateTime frame: 24 MONTHS → From time of surgery through 30 days post-operatively.
    • AddedPercentage of Participants Requiring a Surgical Stapler Articulation Angle Greater Than 45 DegreesTime frame: Intra-operative (during the surgical procedure)
    • AddedOther Complications Attributable to Stapler UseTime frame: From intra-operative procedure through 30 days post-operatively.
    Secondary outcomes 15 added
    What changed in the outcomes
    • AddedIncrease in Operative Time Due to Stapling ComplicationsTime frame: Intra-operative (day of surgery).
    • AddedIntraoperative and Postoperative Adverse EventsTime frame: From initiation of surgery through 30 days post-operatively.
    • AddedRate of Intracorporeal AnastomosisTime frame: Intra-operative (day of surgery)
    • AddedSurgical Conversion RateTime frame: Intra-operative (day of surgery).
    • AddedConversion Rate Due to Stapling-Related ComplicationsTime frame: Intra-operative (day of surgery)
    • AddedLength of ICU StayTime frame: From immediate post-operative transfer until discharge from the ICU (assessed up to 30 days post-surgery).
    • AddedIncrease in ICU Stay Due to Stapling ComplicationsTime frame: From immediate post-operative period through hospital discharge (assessed up to 30 days post-surgery).
    • AddedTotal Length of Hospital StayTime frame: From date of surgery through index hospital discharge (assessed up to 30 days post-surgery).
    • AddedIncrease in Hospital Stay Due to Stapling ComplicationsTime frame: Through index hospital discharge (assessed up to 30 days post-surgery).
    • AddedResection Margin Positivity RateTime frame: Through final histopathology reporting (typically within 14 to 30 days post-surgery).
    • AddedPercentage of Participants With Complete Mesorectal Excision Quality Graded by Quirke ClassificationTime frame: Through final histopathology reporting (typically within 14 to 30 days post-surgery).
    • AddedNumber of Regional Lymph Nodes Harvested per ParticipantTime frame: Through final histopathology reporting (typically within 14 to 30 days post-surgery).
    • Added30-Day Hospital Readmission RateTime frame: From hospital discharge up to 30 days post-surgery.
    • Added30-Day Reoperation RateTime frame: From completion of surgery through 30 days post-surgery.
    • AddedTime to Initiation of Adjuvant TherapyTime frame: From date of surgery up to 30 days post-surgery (or standard post-operative follow-up window).
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07371832
Responsible party
Mohan Ramchandani (Consultant Gastroenterology, Asian Institute of Gastroenterology, India) — Principal investigator
First posted
Jan 28, 2026
Start date
Jan 19, 2026
Primary completion
Feb 28, 2028 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Oct 8, 2026

Study contacts

DR G V RAO, MBBS,MAMS,FRCS
Contact
gvraoaig@gmail.com
+91-9182645727
DR G V RAO, MBBS,MAMS,FRCS
principal investigator · Asian Institute Of Gastroenterology Private Limited

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion